Kevatril

Granisetron, the active ingredient in Kevatril, is a 5‑HT3 receptor antagonist presented as an intravenous solution for intravenous use. It treats chemotherapy‑induced nausea and vomiting and postoperative nausea and vomiting in patients undergoing such therapies, helping to reduce the frequency and severity of these symptoms.

GNH USA supplies Kevatril as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Granisetron acts on the serotonin‑mediated pathway that triggers nausea and vomiting, providing antiemetic control in several clinical settings. - Chemotherapy‑induced nausea and vomiting: reduces the incidence and severity of nausea and vomiting associated with cytotoxic chemotherapy. - Postoperative nausea and vomiting: prevents and treats nausea and vomiting after surgical procedures. - Radiation therapy‑induced nausea and vomiting: alleviates nausea and vomiting caused by radiation treatment.

Granisetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Dizziness: transient light‑headedness. - Fatigue: feeling of tiredness. - Mild hypotension: slight drop in blood pressure.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm, especially in patients with pre‑existing conditions. - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Serotonin syndrome: rare but potentially life‑threatening condition when combined with other serotonergic agents. - Severe hypotension: marked drop in blood pressure leading to syncope.

Before administering Kevatril, consider the following safety measures. - Cardiac assessment: monitor ECG in patients with known cardiac disease. - Concomitant serotonergic drugs: review use to avoid serotonin syndrome. - Hepatic impairment: adjust monitoring as granisetron is metabolized in the liver. - Electrolyte imbalance: use caution as it may predispose to arrhythmias. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Granisetron may interact with several medication classes; awareness of interaction severity is essential.

Major Interactions (Avoid): - Other 5‑HT3 antagonists: combined use can increase risk of QT prolongation. - QT‑prolonging drugs (e.g., quinidine, erythromycin): avoid concurrent administration.

Moderate Interactions (Monitor Closely): - Chemotherapy agents (e.g., cisplatin): monitor for additive antiemetic effect. - Anticholinergic agents: may enhance constipation. - CYP3A4 inhibitors or inducers: may alter granisetron plasma levels.